Eiger Biopharmaceuticals, Inc.

Eiger BioPharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing innovative therapies for serious rare diseases. They focus on first-in-class, well-characterized drugs for life-threatening conditions with high unmet medical needs and no existing approved treatments. Their current pipeline includes therapies for metabolic diseases such as congenital hyperinsulinism and post-bariatric hypoglycemia, and they have previously developed a treatment for Hutchinson-Gilford progeria syndrome, which has been acquired by Sentynl Therapeutics.

Eiger emphasizes a collaborative approach, working with patient advocates, academic centers, and leading experts to deliver much-needed treatments. They boast a senior management team with extensive experience in drug development and commercialization, ensuring a robust and well-structured approach to their mission. Eiger's dedication to tackling rare diseases and their commitment to ethical and impactful research are key components of their overall strategy.

Eiger Biopharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing innovative therapies for serious rare diseases with high unmet medical needs and no approved therapies. Their focus is on bringing first-in-class, well-characterized drugs to market, improving the lives of patients suffering from life-threatening conditions.

Eiger Biopharmaceuticals fosters an inclusive culture that values diverse perspectives and experience. The company encourages its employees to dream beyond limits, break down barriers, and excel in excellence.

Eiger Biopharmaceuticals fosters an inclusive work environment where diverse perspectives and experiences are valued. They encourage team members to break down barriers and excel in excellence, with the belief that this approach will lead to a more innovative and successful company.